Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors
For more information on BPC-157 visit Wikipedia $79.99 - $99.99 You save $79.99 - $99.99 You save $23.99 - $29.99 You save $31.99 - $39.99 You save $39.99 - $49.99 You save $39.99 - $49.99 You save $26.39 - $32.99 You save $39.99 - $49.99 You save Support when you need it
Convenient Administration: Once-weekly injections simplify the treatment regimen
You need syringes, alcohol swabs, and a sharps container
AFVentures, the investment arm of AFWERX, manages the Air Forces SBIR program
Results vary, but many people notice: Earlier improvements from TRT (energy, libido, mental clarity) Gradual improvements from peptides (recovery, sleep, endurance) More consistent symptom relief over time TRT often produces noticeable changes first, while peptides tend to provide supportive benefits that build gradually